Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics

From: Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study

  Women (n = 61) Men (n = 19)
Age, years 60.8 (57.3 to 64.4) 63.4 (59.8 to 66.9)
Disease duration, yearsa 6.0 (2.0 to 15.0) 5.0 (3.0 to 9.0)
Rheumatoid factor positive, N (%) 51 (84) 14 (74)
Erosive disease, N (%) 47 (77) 14 (74)
ESR, mm/ha 16.0 (9.0 to 29.0) 12.0 (9.0 to 15.0)
C-reactive protein, mg/la 2.0 (1.0 to 8.0) 3.0 (1.0 to 9.0)
DAS28 3.3 (3.0 to 3.6) 2.6 (2.1 to 3.0)
HAQ score (0 to 3) 0.7 (0.5 to 0.8) 0.5 (0.2 to 0.7)
Patients on DMARDs, N (%) 59 (97) 19 (100)
Patients on glucocorticoids, N (%) 17 (28) 3 (16)
Glucocorticoids, dose, mg 4.3 (3.4 to 5.3) 4.2 (0.6 to 7.8)
Hypertension, N (%) 33 (54) 13 (68)
MetS, N (%) 12 (20) 12 (63)
  1. Data is presented as mean (95% confidence intervals) for normally distributed variables and as median (interquartile range) for non-parametric variables.
  2. aMedian.
  3. DAS28, 28-joint Disease Activity Score (where a value of >5.1 is regarded as high disease activity, <3.2 is regarded as low activity and <2.6 is regarded as remission); ESR, erythrocyte sedimentation rate; DMARD, disease-modifying antirheumatic drug (for example, methotrexate, sulfasalazine, hydroxychloroquine, cyclosporine, natriumaurotiomalat and azathioprine); HAQ, Health Assessment Questionnaire; MetS, metabolic syndrome.